This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (27)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA  Topic Collections  • Oncology  • Lung Cancer  • Pulmonary Diseases  • Pulmonary Diseases, Other  • Radiologic Imaging  • Radiography  • Alert me on articles by topic  Social Bookmarking   What's this?

The Time Is Now

Thomas L. Petty, MD

JAMA. 2000;284:1977-1980.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Current knowledge and available technology could change the outcome of lung cancer. But screening and even case finding in patients at high risk is still not recommended. No major medical organization in the United States recommends any form of screening for lung cancer. For this reason, lung cancer is not diagnosed until it is symptomatic and usually when it is in advanced and incurable stages. Assume that the following facts are true: In the year 2000, approximately 172,000 patients will be diagnosed as having lung cancer, which represents the most common fatal malignancy in both men and women in the United States (based on 1996 data),¹ and the 5-year survival rate will be only 15%, which is a generous estimate. Simple arithmetic results in 25,800 patients who will survive and 146,200 patients who will have progressive, rapid, and painful deaths from lung cancer, often with bone . . . [Full Text of this Article]

Historical Perspective

Author Affiliations: University of Colorado Health Sciences Center and National Lung Health Education Program, Denver, and Rush-Presbyterian-St Luke's Medical Center, Chicago, Ill.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Cost-effectiveness of Screening for Lung Cancer
Thomas L. Petty
JAMA. 2003;289(18):2357.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Routine Screening for Lung Cancer?: Maybe Someday, but Not Yet
Paul S. Frame
JAMA. 2000;284(15):1980-1983.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A critical appraisal of overdiagnosis: estimates of its magnitude and implications for lung cancer screening
Reich
Thorax 2008;63:377-383.
ABSTRACT | FULL TEXT  

Fragile Histidine Triad Mediated Tumor Suppression of Lung Cancer by Targeting Multiple Components of the Ras/Rho GTPase Molecular Switch
Jayachandran et al.
Cancer Res. 2007;67:10379-10388.
ABSTRACT | FULL TEXT  

Inhaled Corticosteroids and Risk of Lung Cancer among Patients with Chronic Obstructive Pulmonary Disease
Parimon et al.
Am. J. Respir. Crit. Care Med. 2007;175:712-719.
ABSTRACT | FULL TEXT  

Therapeutic bronchoscopy with immediate effect: laser, electrocautery, argon plasma coagulation and stents.
Bolliger et al.
Eur Respir J 2006;27:1258-1271.
ABSTRACT | FULL TEXT  

Lung Cancer Screening: Simulations of Effects of Imperfect Detection on Temporal Dynamics
Chapman et al.
Radiology 2005;234:582-590.
ABSTRACT | FULL TEXT  

Low Lung Function and Incident Lung Cancer in the United States: Data From the First National Health and Nutrition Examination Survey Follow-up
Mannino et al.
Arch Intern Med 2003;163:1475-1480.
ABSTRACT | FULL TEXT  

Cost-effectiveness of Screening for Lung Cancer
Petty
JAMA 2003;289:2357-2357.
FULL TEXT  

Chronic bronchitis among French adults: high prevalence and underdiagnosis
Huchon et al.
Eur Respir J 2002;20:806-812.
ABSTRACT | FULL TEXT  

Improved Survival and Higher Mortality* : The Conundrum of Lung Cancer Screening
Reich
Chest 2002;122:329-337.
FULL TEXT  

Lung Cancer Screening
Granat et al.
JAMA 2001;285:163-164.
FULL TEXT